Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chan Y Cheah

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine|July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, et al.
Haematologica|October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N Shah, Michael Wang, Lindsey E Roeker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patientsRoberto N Miranda, Tariq N Aladily, H Miles Prince, et al.
The Lancet. Haematology|May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trialM Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2024
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin LymphomaMichael Sargent Binkley, Jamie E Flerlage, Kerry J Savage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2025
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular LymphomaMatthew J Maurer, Vit K Prochazka, Tarec Christoffer El-Galaly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2021
Burkitt Lymphoma International Prognostic IndexAdam J Olszewski, Lasse H Jakobsen, Graham P Collins, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine|July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, et al.
Haematologica|October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N Shah, Michael Wang, Lindsey E Roeker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patientsRoberto N Miranda, Tariq N Aladily, H Miles Prince, et al.
The Lancet. Haematology|May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trialM Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2024
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin LymphomaMichael Sargent Binkley, Jamie E Flerlage, Kerry J Savage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2025
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular LymphomaMatthew J Maurer, Vit K Prochazka, Tarec Christoffer El-Galaly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2021
Burkitt Lymphoma International Prognostic IndexAdam J Olszewski, Lasse H Jakobsen, Graham P Collins, et al.
Pageof 13